MTX caused a strong increase (~30 fold) in endogenous AICAR levels in breast cancer cells and mouse embryonic fibroblasts (MEFs) (Fig. 1A, Supplementary Fig. 1), with little effect on the downstream metabolites IMP and AMP, suggesting a blockage in de novo purine biosynthesis at the ATIC step. This evidence concerns the gene ATIC and breast cancer.